News Headlines Article

Drug Pricing Issue Still Plagues Biotech
The Wall Street Journal

It seems that politicians aren’t going to drop the issue of high drug prices any time soon. That is a problem for biotechnology investors.

A dozen congressional Democrats sent a letter to senior officials at the Department of Health and Human Services and National Institutes of Health regarding the high price of a prostate cancer treatment, Xtandi. The members of Congress, who called for hearings over the drug’s price, noted in their letter that existing law allows the NIH to help lower the price of the drug.